Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028889780> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3028889780 abstract "9568 Background: Patients with non-small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group performance status (ECOG PS) have been excluded from immunotherapy clinical trials. We sought to evaluate clinical outcomes to first-line pembrolizumab in patients with advanced NSCLC, a PD-L1 tumor proportion score (TPS) of ≥50%, and an ECOG PS of 2. Methods: We performed a multicenter retrospective analysis of patients with metastatic NSCLC and a PD-L1 tumor proportion score (TPS) of ≥50% (negative for genomic alterations in EGFR and ALK) who received treatment with first-line commercial pembrolizumab. Clinical outcomes were compared in patients based on ECOG PS. Results: Among 234 patients, 83.3% (N = 195) had an ECOG PS of 0 or 1, and 16.7% (N = 39) had an ECOG PS of 2. The baseline clinicopathological characteristics were balanced between the ECOG PS 0-1 vs 2 groups in terms of age, sex, tobacco use, histology, KRAS mutation status, presence of other potentially targetable driver mutations ( BRAF, MET, HER2, RET), history of central nervous system (CNS) disease, and PD-L1 TPS distribution. Compared to patients with an ECOG PS of 0-1, patients with an ECOG PS of 2 had a significantly lower objective response rate (ORR 43.1% vs 25.6%; P = 0.04), a numerically shorter median progression free survival (mPFS 6.6 months vs 4.0 months; P = 0.09), and a significantly shorter median overall survival (mOS 20.3 months vs 7.4 months; P < 0.001). Upon disease progression, patients with an ECOG PS of 2 were significantly less likely to receive second-line systemic therapy compared to patients with an ECOG PS of 0-1 (55.5% vs 14.3%, P < 0.001). Conclusions: Although a subset of patients with an ECOG PS of 2 can respond first-line pembrolizumab, clinical outcomes in this population are poor, and use of second-line systemic therapy is infrequent." @default.
- W3028889780 created "2020-06-05" @default.
- W3028889780 creator A5005948108 @default.
- W3028889780 creator A5022273534 @default.
- W3028889780 creator A5027101531 @default.
- W3028889780 creator A5029805571 @default.
- W3028889780 creator A5030450694 @default.
- W3028889780 creator A5037884911 @default.
- W3028889780 creator A5039160380 @default.
- W3028889780 creator A5041134366 @default.
- W3028889780 creator A5048380048 @default.
- W3028889780 creator A5069854182 @default.
- W3028889780 creator A5075568815 @default.
- W3028889780 creator A5079916769 @default.
- W3028889780 creator A5085305921 @default.
- W3028889780 creator A5086249998 @default.
- W3028889780 creator A5089358409 @default.
- W3028889780 date "2020-05-20" @default.
- W3028889780 modified "2023-10-03" @default.
- W3028889780 title "Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status." @default.
- W3028889780 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.9568" @default.
- W3028889780 hasPublicationYear "2020" @default.
- W3028889780 type Work @default.
- W3028889780 sameAs 3028889780 @default.
- W3028889780 citedByCount "0" @default.
- W3028889780 crossrefType "journal-article" @default.
- W3028889780 hasAuthorship W3028889780A5005948108 @default.
- W3028889780 hasAuthorship W3028889780A5022273534 @default.
- W3028889780 hasAuthorship W3028889780A5027101531 @default.
- W3028889780 hasAuthorship W3028889780A5029805571 @default.
- W3028889780 hasAuthorship W3028889780A5030450694 @default.
- W3028889780 hasAuthorship W3028889780A5037884911 @default.
- W3028889780 hasAuthorship W3028889780A5039160380 @default.
- W3028889780 hasAuthorship W3028889780A5041134366 @default.
- W3028889780 hasAuthorship W3028889780A5048380048 @default.
- W3028889780 hasAuthorship W3028889780A5069854182 @default.
- W3028889780 hasAuthorship W3028889780A5075568815 @default.
- W3028889780 hasAuthorship W3028889780A5079916769 @default.
- W3028889780 hasAuthorship W3028889780A5085305921 @default.
- W3028889780 hasAuthorship W3028889780A5086249998 @default.
- W3028889780 hasAuthorship W3028889780A5089358409 @default.
- W3028889780 hasConcept C121608353 @default.
- W3028889780 hasConcept C126322002 @default.
- W3028889780 hasConcept C143998085 @default.
- W3028889780 hasConcept C2776256026 @default.
- W3028889780 hasConcept C2776694085 @default.
- W3028889780 hasConcept C2776907518 @default.
- W3028889780 hasConcept C2777701055 @default.
- W3028889780 hasConcept C2780057760 @default.
- W3028889780 hasConcept C2780739268 @default.
- W3028889780 hasConcept C2781187634 @default.
- W3028889780 hasConcept C526805850 @default.
- W3028889780 hasConcept C535046627 @default.
- W3028889780 hasConcept C71924100 @default.
- W3028889780 hasConcept C90924648 @default.
- W3028889780 hasConceptScore W3028889780C121608353 @default.
- W3028889780 hasConceptScore W3028889780C126322002 @default.
- W3028889780 hasConceptScore W3028889780C143998085 @default.
- W3028889780 hasConceptScore W3028889780C2776256026 @default.
- W3028889780 hasConceptScore W3028889780C2776694085 @default.
- W3028889780 hasConceptScore W3028889780C2776907518 @default.
- W3028889780 hasConceptScore W3028889780C2777701055 @default.
- W3028889780 hasConceptScore W3028889780C2780057760 @default.
- W3028889780 hasConceptScore W3028889780C2780739268 @default.
- W3028889780 hasConceptScore W3028889780C2781187634 @default.
- W3028889780 hasConceptScore W3028889780C526805850 @default.
- W3028889780 hasConceptScore W3028889780C535046627 @default.
- W3028889780 hasConceptScore W3028889780C71924100 @default.
- W3028889780 hasConceptScore W3028889780C90924648 @default.
- W3028889780 hasLocation W30288897801 @default.
- W3028889780 hasOpenAccess W3028889780 @default.
- W3028889780 hasPrimaryLocation W30288897801 @default.
- W3028889780 hasRelatedWork W11003051 @default.
- W3028889780 hasRelatedWork W12014620 @default.
- W3028889780 hasRelatedWork W12872297 @default.
- W3028889780 hasRelatedWork W17821756 @default.
- W3028889780 hasRelatedWork W18876061 @default.
- W3028889780 hasRelatedWork W19759200 @default.
- W3028889780 hasRelatedWork W20825895 @default.
- W3028889780 hasRelatedWork W3586763 @default.
- W3028889780 hasRelatedWork W6195560 @default.
- W3028889780 hasRelatedWork W3109140 @default.
- W3028889780 isParatext "false" @default.
- W3028889780 isRetracted "false" @default.
- W3028889780 magId "3028889780" @default.
- W3028889780 workType "article" @default.